At BioCrea we turn concepts into drug candidates, creating first-in-class drugs to treat debilitating central nervous system (CNS) diseases. Through the combination of our unique discovery platforms, the use of patient-derived models and clinical data together with an experienced, visionary team, the company discovers and develops new drug candidates for pharmaceutical and biotechnology partners.
January 09, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist validated through pharma partnerships, announced today that the Epilepsy Foundation (Maryland, US) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, Novel Long Term Effective GABAA PAMs (LT GABAA PAM), to treat refractory epilepsy.
October 30, 2013
BIO-Europe to be held November 4-6 in Vienna, Austria
October 07, 2013
BIO Investor Forum to be held October 8-9 in San Francisco, USA